Editage
Research Solutions English Editing AI Solutions Publication Support Journal Finder Corporate Solutions More

Hematological Oncology

eISSN: 1099-1069pISSN: 0278-0232

Check your submission readiness

Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.

Key Metrics

CiteScore
5.3
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q3Oncology
SNIP
1.04
Time to Publish
time-to-publish View Chart
3  Mo

Journal Specifications

Overview
  • Publisher
    WILEY
  • Language
    English
  • Frequency
    Quarterly
General Details
View less
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 41%
4-6 42%
7-9 15%
>9 2%

Topics Covered

Lymphoma
Drug discovery
Rituximab
Diffuse large B-cell lymphoma
Lymphoblastic Leukemia
Lenalidomide
Central nervous system
Hematopoietic stem cell transplantation
Overall survival
Polycythemia vera
Immunotherapy
Poor prognosis
Bendamustine
Minimal residual disease
Follicular lymphoma
B-cell lymphoma
Systematic review
Seroconversion
Progression-free survival
Bortezomib

Year-wise Publication

FAQs

Since when has Hematological Oncology been publishing? Faqs

The Hematological Oncology has been publishing since 1983 till date.

How frequently is the Hematological Oncology published? Faqs

Hematological Oncology is published Quarterly.

Who is the publisher of Hematological Oncology? Faqs

The publisher of Hematological Oncology is WILEY.

How can I view the journal metrics of Hematological Oncology on editage? Faqs

For the Hematological Oncology metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Hematological Oncology? Faqs

The eISSN number is 1099-1069 and pISSN number is 0278-0232 for Hematological Oncology.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Lymphoma, Drug discovery, Rituximab, Diffuse large B-cell lymphoma, Lymphoblastic Leukemia, Lenalidomide, Central nervous system, Hematopoietic stem cell transplantation, Overall survival, Polycythemia vera, Immunotherapy, Poor prognosis, Bendamustine, Minimal residual disease, Follicular lymphoma, B-cell lymphoma, Systematic review, Seroconversion, Progression-free survival, Bortezomib.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.